英国国家卫生与临床优化研究所称，囊性纤维化药物不具成本效益。 - Suppr

Suppr

超能文献

Cystic fibrosis drug is not cost effective, says NICE.

作者信息

Gulland Anne

机构信息

London.

出版信息

BMJ. 2016 Jun 19;353:i3409. doi: 10.1136/bmj.i3409.

DOI:10.1136/bmj.i3409

PMID:27325384

Abstract

摘要

相似文献

Cystic fibrosis drug is not cost effective, says NICE.

BMJ. 2016 Jun 19;353:i3409. doi: 10.1136/bmj.i3409.

Precision Medicine: At What Price?

Am J Respir Crit Care Med. 2015 Sep 15;192(6):658-9. doi: 10.1164/rccm.201507-1428ED.

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.

J Manag Care Spec Pharm. 2018 Oct;24(10):987-997. doi: 10.18553/jmcp.2018.24.10.987.

Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.

Med Lett Drugs Ther. 2016 Mar 28;58(1491):41-2.

Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.

Lancet. 2024 Jun 15;403(10444):2591-2592. doi: 10.1016/S0140-6736(24)00247-2.

Radical new treatments for cystic fibrosis.

Arch Dis Child. 2015 Aug;100(8):727. doi: 10.1136/archdischild-2015-309089. Epub 2015 Jun 15.

Treating Specific Variants Causing Cystic Fibrosis.

JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.

[Causal therapy is available].

MMW Fortschr Med. 2016 Jun 23;158(12):74. doi: 10.1007/s15006-016-8458-8.

Orkambi's Slick Unveiling Puts Insurers in a Bind.

Manag Care. 2015 Aug;24(8):16-7.

[Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].

Med Monatsschr Pharm. 2016 Jan;39(1):42-4.

引用本文的文献

Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden.

Chest. 2022 Dec;162(6):1241-1254. doi: 10.1016/j.chest.2022.07.008. Epub 2022 Jul 19.

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.

Front Pharmacol. 2020 Feb 21;10:1662. doi: 10.3389/fphar.2019.01662. eCollection 2019.

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.

Healthc Policy. 2019 Aug;15(1):70-80. doi: 10.12927/hcpol.2019.25937.

Emerging microRNA Therapeutic Approaches for Cystic Fibrosis.

Front Pharmacol. 2018 Oct 8;9:1113. doi: 10.3389/fphar.2018.01113. eCollection 2018.

Personalized medicine: motivation, challenges, and progress.

Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006.

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.

Drugs. 2016 Aug;76(12):1191-201. doi: 10.1007/s40265-016-0611-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cystic fibrosis drug is not cost effective, says NICE.

BMJ. 2016 Jun 19;353:i3409. doi: 10.1136/bmj.i3409.

Precision Medicine: At What Price?

Am J Respir Crit Care Med. 2015 Sep 15;192(6):658-9. doi: 10.1164/rccm.201507-1428ED.

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.

J Manag Care Spec Pharm. 2018 Oct;24(10):987-997. doi: 10.18553/jmcp.2018.24.10.987.

Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.

Med Lett Drugs Ther. 2016 Mar 28;58(1491):41-2.

Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.

Lancet. 2024 Jun 15;403(10444):2591-2592. doi: 10.1016/S0140-6736(24)00247-2.

Radical new treatments for cystic fibrosis.

Arch Dis Child. 2015 Aug;100(8):727. doi: 10.1136/archdischild-2015-309089. Epub 2015 Jun 15.

Treating Specific Variants Causing Cystic Fibrosis.

JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.

[Causal therapy is available].

MMW Fortschr Med. 2016 Jun 23;158(12):74. doi: 10.1007/s15006-016-8458-8.

Orkambi's Slick Unveiling Puts Insurers in a Bind.

Manag Care. 2015 Aug;24(8):16-7.

[Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].

Med Monatsschr Pharm. 2016 Jan;39(1):42-4.

引用本文的文献

Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden.

Chest. 2022 Dec;162(6):1241-1254. doi: 10.1016/j.chest.2022.07.008. Epub 2022 Jul 19.

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.

Front Pharmacol. 2020 Feb 21;10:1662. doi: 10.3389/fphar.2019.01662. eCollection 2019.

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.

Healthc Policy. 2019 Aug;15(1):70-80. doi: 10.12927/hcpol.2019.25937.

Emerging microRNA Therapeutic Approaches for Cystic Fibrosis.

Front Pharmacol. 2018 Oct 8;9:1113. doi: 10.3389/fphar.2018.01113. eCollection 2018.

Personalized medicine: motivation, challenges, and progress.

Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006.

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.

Drugs. 2016 Aug;76(12):1191-201. doi: 10.1007/s40265-016-0611-2.